JI HA CHOI

Prof. Dr. JI HA CHOI


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Cells
Verified
Journal Article
Open access
PDF file
YLYe-Ji Lee
Ye-Ji Lee
BKBo-Min Kim
Bo-Min Kim
Young-Ho AhnYoung-Ho Ahn
Young-Ho Ahn
JCJI HA CHOI
JI HA CHOI
YCYoun-Hee Choi
Youn-Hee Choi
JKJihee Lee Kang
Jihee Lee Kang
The signal transducer and activator of transcription 6 (STAT6) transcription factor promotes activation of the peroxisome proliferator-activated receptor gamma (PPARγ) pathway in macrophages. Little is known about the effect of proximal signal transduction leading to PPARγ activation for the resolution of acute inflammation. Here, we studied the role of STAT6 signaling in PPARγ activation and the resolution of acute sterile inflammation in a murine model of zymosan-induced peritonitis. First, we showed that STAT6 is aberrantly activated in peritoneal macrophages after zymosan injection. Utilizing STAT6−/− and wild-type (WT) mice, we found that STAT6 deficiency further enhanced zymosan-induced proinflammatory cytokines, such as tumor necrosis factor-α, interleukin (IL)-6, and macrophage inflammatory protein-2 in peritoneal lavage fluid (PLF) and serum, neutrophil numbers and total protein amount in PLF, but reduced proresolving molecules, such as IL-10 and hepatocyte growth factor, in PLF. The peritoneal macrophages and spleens of STAT6−/− mice exhibited lower mRNA and protein levels of PPARγ and its target molecules over the course of inflammation than those of WT mice. The deficiency of STAT6 was shown to impair efferocytosis by peritoneal macrophages. Taken together, these results suggest that enhanced STAT6 signaling results in PPARγ-mediated macrophage programming, contributing to increased efferocytosis and inflammation resolution.

3 June 2016 in Scientific Reports
Verified
Journal Article
Open access
HPHyo Jin Park
Hyo Jin Park
TKTae Hee Kim
Tae Hee Kim
SKSo Won Kim
So Won Kim
SNShin Hye Noh
Shin Hye Noh
KCKyeong Jee Cho
Kyeong Jee Cho
JCJI HA CHOI
JI HA CHOI
Multidrug resistance 3 (MDR3), encoded by the ATP-binding cassette, subfamily B, member 4 gene (ABCB4), localizes to the canalicular membrane of hepatocytes and translocates phosphatidylcholine from the inner leaflet to the outer leaflet of the canalicular membrane. Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare hepatic disease caused by genetic mutations of ABCB4. In this study, we characterized 8 ABCB4 mutations found in PFIC3 patients, using in vitro molecular assays. First, we examined the transport activity of each mutant by measuring its ATPase activity using paclitaxel or phosphatidylcholine. Then, the pathogenic mechanisms by which these mutations affect MDR3 were examined through immunoblotting, cell surface biotinylation, and immunofluorescence. As a result, three ABCB4 mutants showed significantly reduced transport activity. Among these mutants, one mutation A364V, located in intracellular domains, markedly decreased MDR3 expression on the plasma membrane, while the others did not affect the expression. The expression of MDR3 on the plasma membrane and transport activity of A364V was rescued by a pharmacological chaperone, cyclosporin A. Our study provides the molecular mechanisms of ABCB4 mutations and may contribute to the understanding of PFIC3 pathogenesis and the development of a mutation-specific targeted treatment for PFIC3.

11 March 2016 in Scientific Reports
Verified
Journal Article
Open access
HPHyo Jin Park
Hyo Jin Park
EJEun Suk Jung
Eun Suk Jung
KKKyoung Ae Kong
Kyoung Ae Kong
EPEun-Mi Park
Eun-Mi Park
JCJae Hee Cheon
Jae Hee Cheon
JCJI HA CHOI
JI HA CHOI
Crohn’s disease (CD) is a chronic inflammatory bowel disease and a genetic variant in theOCTN2, g.-207G > C is significantly associated with CD susceptibility. This study was aimed to identify novelOCTN2functional promoter variants and their roles in transcriptional regulation using variousin vitroassays. In addition, we investigated the association betweenOCTN2genotypes and CD through genetic analysis using DNA samples from 193 patients with CD and 281 healthy controls. Among the three major promoter haplotypes ofOCTN2identified, one haplotype, H3, showed a significant decrease in promoter activity: two polymorphisms in H3 were associated with a significant reduction in promoter activity. In particular, we found that the reduced transcriptional activity of those two polymorphisms results from a reduction in the binding affinity of the activators, NF-E2 and YY1, to theOCTN2promoter. The functional haplotype of theOCTN2promoter was associated with clinical course of CD such as the disease behavior and need for surgery. However, genetic variants or haplotypes ofOCTN2did not affect the susceptibility to CD. Our results suggest that a common promoter haplotype ofOCTN2regulates the transcriptional rate ofOCTN2and influences the clinical course of CD.

16 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EKEun Young Kwon
Eun Young Kwon
JCJae-Yong Chung
Jae-Yong Chung
HPHyo Jin Park
Hyo Jin Park
BKBo Min Kim
Bo Min Kim
MKMinsuk Kim
Minsuk Kim
JCJI HA CHOI
JI HA CHOI
Organic cation transporter 3 (OCT3) is expressed in various organs in humans and plays an important role in the transport of organic cations and drugs including metformin. In this study, we identified genetic variations of the OCT3 promoter and functionally characterized each variant by in vitro assays. Next, the association between the functional haplotype of the OCT3 promoter and pharmacokinetics of metformin was evaluated. In our study population, 7 variations and 2 major haplotypes were identified, of which H2 haplotype yielded a significantly higher luciferase activity than did the wild type. Two variants of H2, c.-1603G > A and c.-1547T > G, yielded significantly lower luciferase activities, whereas the luciferase activity of another variant, c.-29G > A, was significantly higher. Two transcription factors, Sp1 and USF1, were involved in the regulation of OCT3 transcription. Analysis of clinical data revealed that 25 subjects, either homozygous or heterozygous for H2, showed increased AUCinf and Cmax by 17.2% and 15.9%, respectively [P = 0.016 and 0.031, GMR (90% CI) = 1.17 (1.06–1.29) and 1.17 (1.04–1.31), respectively], compared to the 20 subjects in the control group. Our study suggests that an OCT3 promoter haplotype affects the pharmacokinetics of metformin in Koreans as well as the OCT3 transcription rate.

1 January 2013 in The Korean Journal of Physiology & Pharmacology
Verified
Journal Article
Open access
PDF file
TKTae Hee Kim
Tae Hee Kim
HPHyo Jin Park
Hyo Jin Park
JCJI HA CHOI
JI HA CHOI
Multidrug resistance 3 (MDR3) is expressed on the canalicular membrane of the hepatocytes and plays an important role in protecting the liver from bile acids. Altered ABCB4 gene expression can lead to a rare hepatic disease, low phospholipid-associated cholelithiasis (LPAC). In this study, we characterized 3 ABCB4 mutations in LPAC patients using various in vitro assay systems. We first measured the ability of each mutant to transport paclitaxel and then the mechanisms by which these mutations might change MDR3 transport activity were determined using immunoblotting, cell surface protein biotinylation, and immunofluorescence. Through a membrane vesicular transport assay, we observed that the uptake of paclitaxel was significantly reduced in membrane vesicles expressing 2 ABCB4 mutations, F165I and S320F. Both mutants showed significantly decreased total and cell surface MDR3 expression. These data suggest two missense mutations of ABCB4 may alter function of MDR3 and ultimately can be determined as LPAC-causing mutations.

16 February 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HSHyo Sook Song
Hyo Sook Song
SHSeung Yeon Ha
Seung Yeon Ha
JKJin-Young Kim
Jin-Young Kim
MKMinsuk Kim
Minsuk Kim
JCJI HA CHOI
JI HA CHOI
Solute carrier family (SLC) transporters are expressed in the digestive system and play important roles in maintaining physiological functions in the body. In addition, SLC transporters act as oncoproteins or tumor-suppressor proteins during the development, progression, and metastasis of various digestive system cancers. SLC22A18, a member of the SLC22 gene family, is an orphan transporter with an unknown endogenous substrate. Previous study revealed that SLC22A18 is downregulated in colorectal cancer tissues and that it acts as a suppressor in colorectal cancer, although the effects of SLC22A18 variants on colon cancer cell proliferation, migration, and invasion are unknown. Therefore, in this study, we identified SLC22A18 variants found in multiple populations by searching public databases and determined the in vitro effects of these missense variations on transporter expression and cancer progression. Our results indicated that three missense SLC22A18 variants—p.Ala6Thr, p.Arg12Gln, and p.Arg86His—had significantly lower cell expression than the wild type, possibly owing to intracellular degradation. Furthermore, these three variants caused significantly higher proliferation, migration, and invasion of colon cancer cells than the wild type. Our findings suggest that missense variants of SLC22A18 can potentially serve as biomarkers or prognostic tools that enable clinicians to predict colorectal cancer progression.